Literature DB >> 14753250

First functionalized MRI contrast agent recognizing vascular lesions.

Tatsuhiro Yamamoto1, Kenjiro Ikuta, Keiji Oi, Kohtaro Abe, Toyokazu Uwatoku, Masaharu Murata, Noboru Shigetani, Kengo Yoshimitsu, Hiroaki Shimokawa, Yoshiki Katayama.   

Abstract

A new MRI-contrast agent, EB-DTPA-Gd, that has an Evans Blue analogue as a sensing unit for endothelium lesions, was designed and synthesized. The agent also has diethylenetriamine-N,N,N',N",N"-pentaacetic acid-Gd complex (Gadolinium-DTPA) units, which have been used as detection units for T1-weighted MRI. The EB-DTPA-Gd was able to recognize and adsorb to the vascular endothelium-denuded region of porcine aorta, and to decrease the relaxation time of circumferential water's protons, making possible MR imaging of the endothelium-denuded region. The compound can be employed as a contrast agent for the imaging of vascular lesions using MRI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14753250     DOI: 10.2116/analsci.20.5

Source DB:  PubMed          Journal:  Anal Sci        ISSN: 0910-6340            Impact factor:   2.081


  3 in total

1.  [Initial establishment of digital reference standardized crown models of the primary teeth].

Authors:  S W Feng; H Guo; Y Wang; Y J Zhao; H Liu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-18

2.  A Comparison of Evans Blue and 4-(p-Iodophenyl)butyryl Albumin Binding Moieties on an Integrin αvβ6 Binding Peptide.

Authors:  Ryan A Davis; Sven H Hausner; Rebecca Harris; Julie L Sutcliffe
Journal:  Pharmaceutics       Date:  2022-03-30       Impact factor: 6.525

Review 3.  Recent trends in protein and peptide-based biomaterials for advanced drug delivery.

Authors:  Anastasia Varanko; Soumen Saha; Ashutosh Chilkoti
Journal:  Adv Drug Deliv Rev       Date:  2020-08-29       Impact factor: 15.470

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.